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Abstract
Background: The role of an impaired estimated glomerular filtration rate (eGFR) at hospital admission in the outcome of
acute kidney injury (AKI) after acute myocardial infarction (AMI) has been underreported. The aim of this study was to assess
the influence of an admission eGFR,60 mL/min/1.73 m2 on the incidence and early and late mortality of AMI-associated
AKI.
Methods: A prospective study of 828 AMI patients was performed. AKI was defined as a serum creatinine increase of $50%
from the time of admission (RIFLE criteria) in the first 7 days of hospitalization. Patients were divided into subgroups
according to their eGFR upon hospital admission (MDRD formula, mL/min/1.73 m2) and the development of AKI: eGFR$60
without AKI, eGFR,60 without AKI, eGFR$60 with AKI and eGFR,60 with AKI.
Results: Overall, 14.6% of the patients in this study developed AKI. The admission eGFR had no impact on the incidence of
AKI. However, the admission eGFR was associated with the outcome of AMI-associated AKI. The adjusted hazard ratios (AHR,
Cox multivariate analysis) for 30-day mortality were 2.00 (95% CI 1.11–3.61) for eGFR,60 without AKI, 4.76 (95% CI 2.45–
9.26) for eGFR$60 with AKI and 6.27 (95% CI 3.20–12.29) for eGFR,60 with AKI. Only an admission eGFR of ,60 with AKI
was significantly associated with a 30-day to 1-year mortality hazard (AHR 3.05, 95% CI 1.50–6.19).
Conclusions: AKI development was associated with an increased early mortality hazard in AMI patients with either
preserved or impaired admission eGFR. Only the association of impaired admission eGFR and AKI was associated with an
increased hazard for late mortality among these patients.
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Introduction
Recent North American and European epidemiological studies
have shown that the incidence of acute kidney injury (AKI) is
increasing at an alarming rate [1,2]. The development and
validation of the new AKI diagnostic criteria, namely RIFLE
(Risk, Injury, Failure, Loss, and End-Stage Kidney Disease) [3]
and AKIN (Acute Kidney Injury Network) [4], were significant
advancements in the study of the AKI syndrome and permit
accurate comparisons among different studies. The RIFLE criteria
[3] classify AKI into increasing levels of severity. The first level,
Risk, is defined as an abrupt (within 1–7 days) and sustained
(.24 h) serum creatinine (SCr) increase of at least 1.5 from the
reference SCr or a greater than 25% decrease in the glomerular
filtration rate (GFR) compared to the reference GFR or a urine
output of less than 0.5 mL/kg/h for more than 6 h.
Ischemic heart disease is the leading cause of death among
adults in high-income countries and accounts for a substantial
fraction of the total disease burden globally. AKI is an important
and common complication after acute myocardial infarction
(AMI), affecting from 10 to 55% of the patients (this latter
number referring to patients suffering from cardiogenic shock) [5–
7]. The development of AKI is associated with unfavorable
outcomes and higher mortality after an AMI [5–10]. The
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mechanisms causing AKI in the first few days after an AMI are
multifactorial, including systemic and renal hemodynamic changes
secondary to an impaired cardiac output and an imbalance of
vasodilators and vasoconstrictors, the use of contrast media, and
immunological and inflammatory kidney damage resulting from
crosstalk between the heart and the kidney [11].
The effect of pre-existing renal dysfunction on AKI mortality
remains controversial and conflicting results have been published
[12–16]. Similarly, very few studies have assessed the role of
impaired estimated glomerular filtration rates (eGFRs) at hospital
admission on the mortality of patients with AMI-associated AKI,
and no studies have been explicitly designed to assess whether an
impaired admission eGFR affects the prognosis of AMI-induced
AKI as defined by the RIFLE criteria.
The purpose of this study was to evaluate the association of a
decreased admission eGFR with the incidence and early and late
mortality of patients developing AKI, as defined by the RIFLE
criteria, in the acute phase of a myocardial infarction.
Results
Population characteristics
We evaluated 828 patients with a median age of 65 years
(interquartile range: 54 to 74), 65.5% of whom were male. Our
study population was composed of 7.7% black patients and 92.3%
non-black patients. Overall, at the time of the study, 69% of the
patients had a history of hypertension, 36.7% smoked, 25.7% were
diabetic, 22.6% were dyslipidemic, 41.7% had previously used
angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II
receptor blockers (ARBs), 8.8% had prior percutaneous coronary
intervention (PCI), 15.5% had been affected by prior coronary
artery disease (CAD) with greater than 50% stenosis, 16.3% had
suffered from prior infarction and 8.5% of the patients had
previously undergone coronary artery bypass graft (CABG)
surgery. The median SCr of patients upon hospital admission
was 1.2 mg/dl (interquartile range: 1.0–1.5 mg/dL), and the
admission median eGFR was 63.1 mL/min/1.73 m2 (interquar-
tile range: 47.5–81.3 mL/min/1.73 m2).
The systolic left ventricular function (LVF) was measured in 709
patients and was classified as normal in 29.7%, mildly dysfunc-
tional in 28.6%, moderately dysfunctional in 22.1% and severely
dysfunctional in 19.6% of them. ST elevation myocardial
infarction (STEMI) was diagnosed in 50.2% of the patients,
20.9% of whom presented with a Killip class .I and 54.5% of
whom presented with an anterior wall infarction. The overall in-
hospital mortality was 13.6%.
AKI incidence and mortality
AKI occurred in 121 (14.6%) of the patients, with 76 patients of
these patients (9.2%) in the Risk category, 37 patients (4.5%) in the
Injury category and 8 patients (1%) in the Failure category. The
30-day mortality rate was 38.8% (8.8% in the group without AKI,
p,0.001), and the 30-day to 1-year mortality rate was 25.4%
(13% in the group without AKI, p-value = 0.006).
Comparison between patients with impaired and non-
impaired admission eGFRs
Patients with an impaired eGFR had a median admission SCr
of 1.5 mg/dl (interquartile range: 1.3–1.8 mg/dL) and a median
admission eGFR of 46.1 mL/min/1.73 m2 (interquartile range:
36.7–52.8 mL/min/1.73 m2). Patients with non-impaired eGFR
had a median admission SCr of 1.0 mg/dL (interquartile range:
0.8–1.2 mg/dl) and a median admission eGFR of 79.2 mL/min/
1.73 m2 (interquartile range: 68.5–96.1 mL/min/1.73 m2).
Among the study population, 46% had an admission
eGFR,60 mL/min/1.73 m2. When compared to the group of
patients with an admission eGFR$60 mL/min/1.73 m2, this
group was composed of a smaller proportion of men; was
significantly older; and had a significantly increased prevalence
of hypertension, diabetes, prior infarction, prior use of ACEIs/
ARBs and previously documented CAD, PCI or CABG. A
significantly higher number of patients with an admission
eGFR$60 mL/min/1.73 m2 had an admission heart rate (HR)
.100 beats/min and a systolic blood pressure (SBP)
,100 mmHg. These patients were also more likely to have non-
ST elevation myocardial infarction (NSTEMI). When presenting
with STEMI, these patients exhibited a higher frequency of Killip
class .I (Table 1).
Patients with an impaired admission eGFR were significantly
less likely to receive b-blockers, ACEIs/ARBs, and clopidogrel and
were more likely to receive diuretics. Additionally, they were
significantly less likely to undergo coronary angiography, PCI,
CABG or any revascularization interventions during their
hospitalization than those with an admission eGFR$60 mL/
min/1.73 m2. STEMI patients with an impaired admission eGFR
were significantly less likely to receive thrombolytic treatment or
any type of reperfusion therapy than subjects with an admission
eGFR$60 mL/min/1.73 m2. There was no difference between
the two groups in the thrombolysis in myocardial infarction
(TIMI) 3 flow rate or in the favorable reperfusion criteria after
reperfusion treatment (table 2).
Impaired admission eGFR had no impact on the incidence of
AKI, which was similar between the two groups. Patients with an
impaired admission eGFR were hospitalized significantly longer
and had significantly greater 30-day and 30-day to 1-year
mortality rates than those with an admission eGFR$60 mL/
min/1.73 m2 (Table 2).
Comparison of demographic and clinical characteristics
based on admission eGFR and the presence of AKI
Among the patients who had an admission eGFR$60 mL/
min/1.73 m2, those who had AKI tended to be older (p,0.001),
were more likely to have a HR.100 beats/min (p= 0.013) and
were more likely to have a history of diabetes (p = 0.009). Among
patients with admission eGFRs,60 mL/min/1.73 m2, there were
no significant differences between subgroups with and without
AKI (Table 3).
Influence of admission eGFR and AKI on mortality—
univariate analysis
Among the patients who did not develop AKI, an impaired
admission eGFR was associated with significantly higher 30-day
and 30-day to 1-year mortality rates compared to patients with an
admission eGFR$60 mL/min/1.73 m2 (figures 1 and 2 and
Table 4).
Among the patients who developed AKI, the 30-day mortality
rate was similar between the groups with preserved or impaired
admission eGFR. The 30 day to 1-year mortality rate was
significantly higher in patients with an impaired admission eGFR
and AKI compared to patients with an admission eGFR$60 mL/
min/1.73 m2 and AKI (figures 1 and 2 and Table 4).
Influence of admission eGFR and AKI on mortality—Cox
multivariate analyses
The association between mortality and impaired admission
eGFR and/or AKI development was evaluated among the four
groups.
Acute Kidney Injury after Myocardial Infarction
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Table 1. Comparison of admission characteristics upon hospitalization between patients with not-impaired or impaired admission
eGFR.
Characteristics Total Cohort (n =828) a-eGFR$60 (n=447) a-eGFR,60 (n =381) p-value**
Age (y) 65 (54–74) 59 (49–71) 70 (61–75) ,0.001
Male 65.5% 72.0% 57.7% ,0.001
History of hypertension 69% 57.9% 81.9% ,0.001
Current smoker 36.7% 44.5% 27.6% ,0.001
History of diabetes 25.7% 19.2% 33.3% ,0.001
Previous PCI 8.8% 6.7% 11.3% 0.021
Previous CABG 8.5% 5.1% 12.3% ,0.001
Prior CAD (stenosis .50%) 15.5% 10.7% 21.0% ,0.001
Previous AMI 16.3% 12.3% 21.0% 0.001
Prior use of ACEI/ARB* 41.7% 31.1% 54.1% ,0.001
STEMI 50.2% 55.9% 43.6% ,0.001
aSBP,100 mm Hg{ 6.3% 3.6% 9.5% 0.001
aHR (beats/min) 80 (70–95) 80 (70–92) 80 (70–100) 0.249
aHR .100 beats/min 16.5% 13.2% 20.5% 0.005
Killip class .1 { 20.9% 15.6% 28.9% 0.001
a-eGFR, admission estimated glomerular filtration rate (mL/min/1.73 m2); PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CAD, coronary
artery disease; AMI, acute myocardial infarction; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; STEMI, ST elevation myocardial
infarction; aSBP, admission systolic blood pressure; aHR, admission heart rate. Continuous variables are presented as median values (with interquartile ranges).
Categorical variables are presented as percentages.
*n = 821 for the total cohort, n = 444 for a-eGFR$60 mL/min/1.73 m2, and n = 377 for a-eGFR,60 mL/min/1.73 m2.
{n = 827 for the total cohort; n = 380 for a-eGFR,60 mL/min/1.73 m2.
{n = 416 (STEMI patients).
**comparison between eGFR$60 and ,60 mL/min/1.73 m2.
doi:10.1371/journal.pone.0035496.t001
Table 2. Comparison between patients with not impaired and impaired admission eGFR regarding treatment, incidence of AKI,
length of hospitalization and mortality.
Variables Total Cohort (n=828) a-eGFR$60 (n =447) a-eGFR,60 (n =381) p-value
ß-blockers 93.5% 95.1% 91.6% 0.043
ACEI/ARB 97.2% 98.7% 95.5% 0.006
Diuretics 57.2% 48.5% 67.5% ,0.001
Clopidogrel 82.2% 85.7% 78.2% 0.005
Coronary angiography 82% 89.3% 73.5% ,0.001
PCI 49% 53.7% 43.6% 0.004
CABG 6.4% 8.5% 3.9% 0.007
Any revascularization* 55.2% 61.5% 47.8% ,0.001
Thrombolytic treatment 33.6% 40% 23% ,0.001
Primary PCI for STEMI 48.3% 47.6% 47.6% 0.998
Any reperfusion therapy{ 81% 86.4% 69.9% ,0.001
TIMI 3 flow rate after reperfusion treatment 86.5% 83.7% 90.8% 0.131
Favorable reperfusion criteria 73% 76.5% 66.9% 0.064
Incidence of AKI 14.6% 13.4% 16.0% 0.293
Length of hospitalization (d) 7.43 (4.4–13.3) 6.9(4.3–12.2) 8.1(4.4–15.1) 0.014
30-day mortality 13.2% 8.9% 18.1% ,0.001
30-day to 1-year mortality 14.4% 8.5% 22.5% ,0.001
a-eGFR, estimated glomerular filtration rate upon admission (mL/min/1.73 m2); PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; ACEI,
angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers. Continuous variables are presented as median values (with interquartile ranges).
Categorical variables are presented as percentages.
*With PCI or CABG.
{With primary PCI or a thrombolytic.
doi:10.1371/journal.pone.0035496.t002
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30-day survival. An admission eGFR,60 mL/min/1.73 m2
without AKI was associated with an adjusted hazard ratio (AHR)
for death of 2.00 (95% CI 1.11–3.61). Patients with a non-
impaired admission eGFR and AKI had a death AHR of 4.76
(95% CI 2.45–9.26). The patients with an impaired admission
eGFR and AKI had the worst outcome with a mortality AHR of
6.27 (95% CI 3.20–12.29). The reference group was composed of
patients with an admission eGFR$60 mL/min/1.73 m2 without
AKI (figures 1 and 3 and table 5).
30-day to 1-year survival. The 30-day to 1-year survival
rate was estimated for those patients who survived for 30 days after
AMI. Neither an impaired admission eGFR without AKI nor a
non-impaired admission eGFR with AKI were associated with late
mortality. In contrast, an impaired admission eGFR with AKI was
associated with a death AHR of 3.05 (95% CI 1.50–6.19) (figures 2
and 4 and table 6).
Discussion
Influence of admission eGFR on mortality due to AKI
Previous studies have demonstrated that either an impaired
renal function at admission or the subsequent development of AKI
negatively affects the outcome of patients suffering from an AMI
[9,10,17,18]. However, none of the studies prospectively and
Table 3. Comparison of demographic and clinical characteristics based on admission eGFR and AKI development.
admission eGFR$60 admission eGFR,60
Characteristics without AKI (n =387) with AKI (n =60) without AKI (n =320) with AKI (n =61) p-value
Age (y) 59 (48–70) 70 (55–78)* 69 (61–75) 72 (61–77) ,0.001
Male 73.1% 65.0% 57.8% 57.4% ,0.001
Hypertension 56.6% 66.7% 81.3% 85.2% ,0.001
Current smoker 45.7% 36.7% 26.9% 31.1% ,0.001
Diabetes 17.3% 31.7%{ 32.2% 39.3% ,0.001
Previous PCI 6.2% 10.0% 12.5% 4.9% 0.019
Previous CABG 5.4% 3.3% 12.2% 13.1% 0.003
Prior CAD 10.9% 10.0% 20.9% 21.3% 0.001
Previous AMI 21.0% 13.3% 21.3% 19.7% ,0.009
Prior use of ACEIs/ARBs 29.9% 38.3% 54.7% 50.8% ,0.001
STEMI 55.0% 61.7% 41.3% 55.7% ,0.001
Admission SBP,100 mm Hg 2.8% 8.3% 8.2% 16.4% ,0.001
Admission HR { 80 (70–92) 86 (70–100) 80 (70–97) 88 (77–110) 0.047
Admission HR .100 { 11.6% 23.3%** 19.4% 26.2 0.002
eGFR, estimated glomerular filtration rate (mL/min/1.73 m2); PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CAD, coronary artery disease;
AMI, acute myocardial infarction; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; STEMI, ST elevation myocardial infarction; aSBP,
systolic blood pressure; HR, heart rate. Continuous variables are presented as median values (with interquartile ranges) and were analyzed by the Kruskal-Wallis test
followed by Dunn’s post-test. Categorical variables are presented as percentages and were analyzed by x2 statistics with Bonferroni correction for post-test multiple
comparisons.
*p,0.001,
{p = 0.009,
**p = 0.013, admission eGFR$60, with AKI versus without AKI,
{(beats/min).
doi:10.1371/journal.pone.0035496.t003
Figure 1. Hospital admission eGFR, AKI development and 30-day mortality rates after acute myocardial infarction. Hazard ratio (Cox
multivariate analysis, left) and crude mortality (right).
doi:10.1371/journal.pone.0035496.g001
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simultaneously assessed the role of an impaired admission eGFR
and AKI development, as defined by RIFLE criteria, on the
outcome of AMIs.
In this study, the use of Cox multivariate analysis clearly
revealed that the development of AKI was the predominant factor
associated with increased 30-day mortality, while an impaired
admission eGFR was strikingly associated with an increased long-
term mortality in patients with AMI-associated AKI. In fact,
during the period from 30 days to one year after hospital
admission, only the patients with an impaired admission eGFR
and AKI had significantly lower survival rates. These results
suggest that early mortality was largely related to the effects of
AKI, while long-term outcomes were influenced by AKI
development in addition to previously impaired renal function.
The factors leading to the remarkably higher mortality among
patients with an impaired admission eGFR and AMI-associated
AKI are not evident. One possible explanation for these poorer
outcomes may be the combination of a powerful AKI-induced
surge of inflammation along with the high prevalence of
cardiovascular risk factors, such as older age, diabetes, hyperten-
sion and a pro-inflammatory milieu already present in the group of
patients with impaired admission eGFR [11,19]. In addition, we
observed differences in the AMI treatment received in the two
groups; patients in the group with admission eGFRs,60 mL/
min/1.73 m2 were less likely to receive pharmacological therapy
or to undergo interventional procedures. Other authors have also
observed that AMI patients with an impaired admission eGFR
were offered less AMI treatment [20–23]. More severe cardiac
disease was also associated with higher mortality in the current
study. However, an association between an impaired admission
eGFR and the development of AKI remained independently
associated with a higher mortality hazard after controlling for
variables possibly related to cardiac function, past history and
treatment. Similarly, the overlap between impaired admission
eGFR and AKI continued to be independently associated with a
higher mortality hazard after correction for the characteristics that
distinguish the group with impaired admission eGFRs from the
rest of the patient groups.
A limited number of studies have assessed the role of admission
eGFR on the outcome of AMI-associated AKI. A study on
STEMI patients [5] revealed that AKI, arbitrarily defined as a
creatinine elevation .0.5 mg/dL during hospitalization, was
associated with increased 30-day and 1-year mortality rates. The
study did not find any effect of the admission renal function on
mortality due to AKI. It is important to note the differences
between this study and our own. We used the RIFLE definition
and a time frame of seven days for AKI diagnosis, and we
compared the mortality data among the groups by a multivariate
Cox proportional hazards regression. On the other hand, Gold-
berg et al. non-discriminately used an arbitrary absolute SCr
Figure 2. Hospital admission eGFR, AKI development and 30-day to 1-year mortality rates after acute myocardial infarction. Hazard
ratio (Cox multivariate analysis, left) and crude mortality (right). Note that only the combination of an admission eGFR,60 mL/min/1.73 m2 with AKI
was associated with a higher late mortality. * 30-day to 1-year mortality rates were estimated for patients who survived for 30 days after AMI.
doi:10.1371/journal.pone.0035496.g002
Table 4. Influence of impaired admission eGFR on 30-day and 30-day to 1-year mortality rates with and without AKI development
(univariate analysis).
a-eGFR$60 a-eGFR,60 p-value
Mortality at day 30 n % (n) n % (n)
Without AKI 387 4.9% (19) 320 13.4% (43) ,0.001
With AKI 60 35% (21) 61 42.6% (26) 0.39
Mortality at 30-days to 1-year* n % (n) n % (n)
Without AKI 308 8.1% (25) 217 19.8% (43) ,0.001
With AKI 35 11.4% (4) 32 40.6% (13) 0.006
a-eGFR, admission estimated glomerular filtration rate (mL/min/1.73 m2); AKI, acute kidney injury.
*estimated for those surviving at day 30 and who had complete follow-ups for up to one year or death.
doi:10.1371/journal.pone.0035496.t004
Acute Kidney Injury after Myocardial Infarction
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increase during any time point of hospitalization for AKI diagnosis
and compared the mortality by logistic regression. Another study
[24] evaluating AMI patients showed that AKI, defined as a
$25% decrease in eGFR at any point during hospitalization, was
associated with a higher 1-year mortality rate. The authors used
univariate analysis to assess the relationship between AKI and
chronic kidney disease (CKD), diagnosed as an admission eGFR
between 15 and 59 mL/min, and they concluded that AKI was a
risk factor for 1-year mortality independent of admission eGFR.
This conclusion must be taken with reservations because they did
not control for any potential confounding variables in their
analysis. Parikh et al. [6] examined the long-term mortality rate
after post-MI AKI in a large cohort of patients. In a secondary
analysis, the authors suggested that AKI in addition to CKD was
associated with a lower risk of death compared to AKI without
CKD. The inconsistency of these results with those of the present
study could be due to the design differences between the two
studies and to the limitations of the study by Parikh et al. [25]. We
used RIFLE criteria during the first week of hospitalization to
diagnose AKI, while Parikh et al. defined AKI by graded absolute
changes in the serum creatinine at any point during hospitaliza-
tion. As the authors acknowledged in their manuscript, ‘‘sicker
patients are more likely to have longer hospitalizations and thus
undergo more blood work and assessment of renal function,
increasing the probability of detecting a change in serum
creatinine level’’. Another important difference between ours
and Parikh’s’ studies is that we assessed data from 2004 to 2008 in
a prospective database, and Parikh et al. used a retrospective
database to assess patients hospitalized from 1994 to 1996. As they
indicated in their manuscript, the treatment of AMI has
substantially improved in the last decade. Further limitations that
may affect their secondary analysis are acknowledged by the
authors, including the high number of excluded patients (93,784–
40% of the total cohort) and the lack of information concerning
the pharmacological treatment of these patients, making it
impossible to control for these therapies in the Cox analysis, as
was done in the present study. Finally, the left ventricular ejection
fraction (a strong predictor of long-term survival after AMI) was
unavailable in 39.4% of the non-AKI patients in this previous
study.
Overall, studies regarding the prognostic effect of pre-existing
renal dysfunction on mortality after AKI have reported conflicting
results. Some reported a decrease in early mortality in patients
with overlapping AKI and CKD compared to the controls in
unselected cohorts of critically ill patients [26–28]. Conversely, a
Figure 3. COX curve for 30-day survival among the four groups
divided into admission eGFR and AKI development. Admission
eGFR, estimated glomerular filtration rate upon admission (mL/min/
1.73 m2); AKI, acute kidney injury. For the comparison between
admission eGFR$60 without AKI and admission eGFR,60 without
AKI, p = 0.020; between admission eGFR$60 without AKI and admission
eGFR$60 with AKI, p,0.001; for admission eGFR$60 without AKI and
admission eGFR,60 with AKI, p,0.001.
doi:10.1371/journal.pone.0035496.g003
Table 5. Cox proportional hazards model for 30-day
mortality.
Groups AHR (95% CI) p-value
admission eGFR$60 without AKI (n = 387) 1.0
admission eGFR,60 without AKI (n = 320) 2.00 (1.11–3.61) 0.020
admission eGFR$60 with AKI (n = 60) 4.76 (2.45–9.26) ,0.001
admission eGFR,60 with AKI (n = 61) 6.27 (3.20–12.29) ,0.001
eGFR, estimated glomerular filtration rate (mL/min/1.73 m2); AKI, acute kidney
injury; AHR, adjusted hazard ratio; CI, confidence interval.
The model was adjusted for age creatine phosphokinase-MB, and admission
glycemia (categorized by quartiles with the first as a reference), gender (females
were used as the reference), history of prior coronary artery bypass graft, ST
elevation myocardial infarction, history of diabetes, history of hypertension,
admission Killip class .I, systolic blood pressure ,100 mmHg, admission heart
rate .100 beats/min, clopidogrel use during hospitalization, use of diuretics,
coronary angiography during hospitalization, reinfarction, severe systolic left
ventricular dysfunction and any percutaneous coronary intervention performed
during hospitalization.
doi:10.1371/journal.pone.0035496.t005
Figure 4. COX curve for 30-day to 1-year survival among the
four groups divided into admission eGFR and AKI develop-
ment. Admission eGFR, estimated glomerular filtration rate upon
admission (mL/min/1.73 m2); AKI, acute kidney injury. P = 0.002 for the
comparison between admission eGFR$60 without AKI and admission
eGFR,60 with AKI, while the differences between the others groups
with an admission eGFR$60 without AKI were non-significant. * 30-day
to 1-year mortality rates were estimated for patients who survived for
30 days after AMI.
doi:10.1371/journal.pone.0035496.g004
Acute Kidney Injury after Myocardial Infarction
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study by Kolli et al, assessing 1,359 cardiac surgery patients [13]
showed that an impaired admission eGFR (,60 mL/min) was
associated with a higher mortality rate in patients who developed
AKI. Similarly, a study by Wu et al, which analyzed a very large
cohort of patients who developed postoperative AKI showed that
those patients with previous CKD had a higher risk of long-term
mortality than the patients without CKD [16]. Recently, an
interesting and elegant experimental study by Skott et al, showed
that even mild CKD led to an increased mortality rate in a rodent
model of AKI and multiple organ failure [14].
Influence of admission eGFR on the incidence of AKI
In this study, there was no difference in the incidence of AKI
between patients with an admission eGFR,60 mL/min or an
eGFR$60 mL/min. Similarly, Lombardi et al. [29] studied 1,749
patients after cardiac surgery and found no difference in the rates
of AKI development (41.9 versus 43.4%, respectively) between
patients with an admission eGFR,60 or an eGFR$60 mL/min.
Other studies have reported an association between pre-existing
CKD and AKI development [5,30]. It is unclear whether this
association exists as a true primary cause-and-effect relationship or
if this association is due to confounding secondary comorbidities
that are associated with CKD, the increased exposure of this
population to nephrotoxic insults or the study bias. In fact, most of
the studies correlating increased AKI incidence with previous
CKD utilized a retrospective design with methodological short-
comings, including improper adjustments for comorbidities in
multivariate analyses. Furthermore, these studies often lack a
standardized protocol for the diagnosis of CKD and AKI.
Although not assessed in the present study, proteinuria, a
marker of renal injury, has been recently identified as an
important risk factor for the development of AKI in various
situations, such as following cardiac surgery [31–35].
Study limitations
This was a single-center observational prospective cohort study.
Systolic left ventricular function as assessed by echocardiogra-
phy was not always determined by the same observer.
The present study cannot be used to determine the effect of
CKD on the incidence and mortality of AKI because the
definition of CKD [36] requires the documentation of kidney
damage for three or more months. This time assessment is
obviously difficult to obtain in this type of study, as most patients
have not undergone a renal function evaluation prior to their
admission for an acute illness.
AKI incidence was probable underestimated. The reference
SCr used for AKI diagnosis was the one obtained at the hospital
admission. It is likely that some patients were hospitalized already
with AKI, but because there was no SCr increase from the
reference SCr during the hospital stay, they were misdiagnosed as
non-AKI.
Finally, SCr measurements were performed on a clinical need
basis after discharge from the intensive care unit, which could also
lead to an underestimation of the incidence of AKI.
Conclusions
AKI development was negatively associated with the early
outcomes of AMI in patients with either non-impaired or impaired
admission eGFR. On the other hand, the presence of a low
admission eGFR in patients with acute myocardial infarction-
associated AKI was clearly associated with a significantly poorer
long-term prognosis. Additionally, this study confirmed, using
RIFLE criteria that AKI development in AMI patients is frequent
and is associated with a high mortality rate.
These results strongly suggest that patients with an impaired
admission eGFR should have their renal function monitored
closely after an acute myocardial infarction. Clinical measures for
the prevention and early diagnosis of AKI must be taken to
potentially increase the survival rates of these patients. Moreover,
patients with an impaired admission eGFR who develop AKI must
have an extremely careful and detailed long-term follow-up to try
to avoid the poor long-term outcomes described in this study.
Methods
Ethics statement
The study protocol was approved by the Institutional Ethics
Committee on September 21, 2009 (‘‘Comiteˆ de E´tica em
Pesquisa em Seres Humanos da Faculdade de Medicina de Sao
Jose´ do Rio Preto’’, Sao Jose´ do Rio Preto, Brazil, process 4988/
2009), who agreed that informed consent was unnecessary due to
the purely observational and non-interventional nature of this
study (‘‘Resoluc¸a˜o CNS 196/96’’).
Patients
A total of 1,012 consecutive patients (October 2004–December
2008) with a STEMI or with a NSTEMI [37] were assessed using
a prospective database on thoracic pain from a single center.
Among the 1,012 patients, 184 were not included in the study
because they met the following exclusion criteria: admission
SCr$6.0 mg/dL, admission eGFR,15.0 mL/min/1.73 m2 or
chronic dialysis (21 patients); death within 48 hours of admission
(49 patients); lack of at least two SCr measurements in the first
seven days of hospitalization (94 patients); obstructive AKI (3
patients); and a hospital stay ,48 hours (17 patients).
Only the first hospital admission was considered if a patient had
more than one hospitalization for AMI during the study period.
Systolic left ventricular function
Systolic left ventricular function was classified as either normal
function or mild, moderate or severe dysfunction and was assessed
by echocardiography (based on medical need) in 85.6% of the
patients [38].
Table 6. Cox proportional hazards model for 30-day to 1-year
mortality*.
Groups AHR (95% CI) p-value
admission eGFR$60 without AKI (n = 308) 1.0
admission eGFR,60 without AKI (n = 217) 1.12 (0.65–1.89) 0.696
admission eGFR$60 with AKI (n = 35) 0.75 (0.26–2.16) 0.588
admission eGFR,60 with AKI (n = 32) 3.05 (1.50–6.19) 0.002
*Estimated for patients who survived for 30 days after AMI.
eGFR, estimated glomerular filtration rate (mL/min/1.73 m2); AKI, acute kidney
injury; AHR, adjusted hazard ratio; CI, confidence interval.
The model was adjusted for age, admission glycemia (categorized by quartiles
with the first as a reference), gender (females were used as the reference), ST
elevation myocardial infarction, history of diabetes, history of hypertension,
prior use of angiotensin-converting enzyme inhibitors or angiotensin II receptor
blockers, admission Killip class .I, admission heart rate .100 beats/min,
clopidogrel use during hospitalization, diuretics use, coronary angiography
during hospitalization, reinfarction, severe systolic left ventricular dysfunction
and any percutaneous coronary intervention performed during hospitalization.
doi:10.1371/journal.pone.0035496.t006
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SCr measurements, eGFR calculation and diagnostic
criteria for AKI
The SCr level was obtained at the time of hospital admission
and daily during the intensive care unit (ICU) stay. After ICU
discharge, the SCr was measured as needed. The SCr was assessed
using the Jaffe´ colorimetric method (ADVIATM 1650, Bayer,
Germany).
The admission eGFR was assessed by the Modification of Diet
in Renal Disease (MDRD) formula [39] (mL/min/1.73 m2):
GFR=186.36SCr 21.154 * age 20.203 * 1.212 (if patient is black) *
0.742 (if female). It should be noted that this equation was not
specifically validated for this study population.
Patients were divided into 4 subgroups:
admission eGFR$60 without AKI
admission eGFR,60 without AKI
admission eGFR$60 with AKI
admission eGFR,60 with AKI
Patients were diagnosed with AKI if they had a SCr increase of
$1.5-fold over the admission value within the first seven days of
hospitalization (RIFLE criteria, stage Risk). The RIFLE criteria
definition of AKI using urinary output (,0.5 mL/kg for 6 h for
Risk) was not used in this study [40].
Outcomes
The primary endpoints were death from any cause within 30
days and 30-day to 1-year mortality for those patients who
survived after 30 days. Patient follow-up after discharge was
conducted either by an electronic hospital system records review
or by mail or telephone contact of patients.
Statistical Analysis
Patients were categorized based on their admission eGFR (,60
or $60 mL/min/1.73 m2) and on whether they developed AKI
during their hospitalization. The demographics and clinical
characteristics (presented as median values with interquartile
ranges) were compared by the Student’s t-test, Mann-Whitney test
or Kruskal-Wallis test followed by Dunn’s post-test for continuous
variables. The categorical variables (presented as numbers and
percentages) were compared using either x2 statistics or Fisher’s
exact test. Bonferroni corrections were used for post-test multiple
comparisons.
Separate analyses were performed on the 30-day mortality rates
after the onset of AMI (n= 828) and on the 30-day to 1-year
mortality rates for those patients (n = 699) who survived past day
30. Patients who had been part of the follow-up period for less
than one year were not included (n= 107) in the descriptive and
univariate analyses of the mortality rates at that time point.
We performed multivariate Cox proportional hazards regres-
sion analyses to evaluate the two mortality periods. The
association between mortality and admission eGFR and AKI
development in the four subgroups in which patients were divided
was evaluated, controlling for clinically important variables and for
variables with a p-value,0.15 in the univariate analyses of
mortality in each period. The proportional hazards test and the
plotted cumulative survival estimate after the ln (-ln) transforma-
tion suggested that the hazards of these variables were propor-
tional for the period analyzed.
In the first period of multivariate Cox proportional hazards
regression analysis, the follow-up was censored at day-30 and was
adjusted for age, creatine phosphokinase MB (CPK-MB) and
admission glycemia (categorized by quartiles with the first as a
reference), gender (females were used as the reference), history of
prior CABG, STEMI, history of diabetes, history of hypertension,
admission Killip class .I, SBP,100 mmHg, admission HR .100
beat/min, clopidogrel use during the hospitalization, use of
diuretics, coronary angiography during the hospitalization,
reinfarction, severe systolic left ventricular dysfunction (LVD)
and any PCI performed during the hospitalization.
The multivariate Cox proportional hazards regression analysis
of 30-day to 1-year mortality rates included all patients who
survived for 30 days after AMI with censoring at 365 days. The
controlling variables were the same used for the 30-day analysis
with the exception of CPK-MB, history of prior CABG,
SBP,100 mmHg and reinfarction. The prior use of ACEIs or
ARBs was also controlled in this analysis.
Differences were considered statistically significant by a two-
tailed p-value,0.05 and a confidence interval (CI) of 95%.
Analyses were performed with SPSS statistical software (version
15.0, Chicago, IL, USA).
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